On-demand virtual event
Biological & Medicinal Chemistry
Prior to 2000, many drugs that formed a covalent bond with targets did so non-selectively, which often led to undesired side effects when compared to non-covalent drugs. This led to the belief that covalent inhibitors were not ideal drug candidates resulting in limited development by the pharmaceutical industry. However, covalent drugs have experienced a remarkable resurgence in the last few years as evidenced by the growing number of approvals by the USFDA, including the 2021 approval of Sotorasib to treat lung cancer that was recently featured on ACS Webinars. In fact, from 2013-2021, eight drugs utilizing targeted covalent inhibitors (TCI) to treat lymphoma, lung cancer, and breast cancer have been approved.
Today, scientists have designed “warheads” with remarkable functionality that exhibit finely tuned reactivity, which only form covalent bonds when positioned at the desired target. Join a panel of experts as they explore the concept of targeted covalent inhibitors, their application in tackling previously unmanageable targets, and gain valuable insights into the covalent inhibitor landscape. Register now to discover current trends related to commonly employed warheads, their target proteins, and therapeutic indications.
This ACS Webinar is co-produced with CAS, a division of the American Chemical Society.
What You Will Learn
Meet The Experts
Gary Gustafson, Senior Customer Success Specialist, CAS, a division of the American Chemical Society
Neil Dhawan, Co-founder and CEO, Totus Medicines
Qiongqiong Angela Zhou, Manager, Scientific Analysis and Insights, CAS, a division of the American Chemical Society
Keep learning. Excel in your career.
Choose from more than 200 courses in seven different categories, taught by experts in the chemistry community, online and in person.